Home > Research > Publications & Outputs > Prevalence, risk factors and outcomes of cardia...

Text available via DOI:

View graph of relations

Prevalence, risk factors and outcomes of cardiac disease in cystic fibrosis: A multinational retrospective cohort study

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Prevalence, risk factors and outcomes of cardiac disease in cystic fibrosis: A multinational retrospective cohort study. / Frost, Freddy; Nazareth, Dilip; Fauchier, Laurent et al.
In: European Respiratory Journal, Vol. 62, No. 4, 2300174, 01.10.2023.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

Frost, F, Nazareth, D, Fauchier, L, Wat, D, Shelley, J, Austin, P, Walshaw, MJ & Lip, GYH 2023, 'Prevalence, risk factors and outcomes of cardiac disease in cystic fibrosis: A multinational retrospective cohort study', European Respiratory Journal, vol. 62, no. 4, 2300174. https://doi.org/10.1183/13993003.00174-2023

APA

Frost, F., Nazareth, D., Fauchier, L., Wat, D., Shelley, J., Austin, P., Walshaw, M. J., & Lip, G. Y. H. (2023). Prevalence, risk factors and outcomes of cardiac disease in cystic fibrosis: A multinational retrospective cohort study. European Respiratory Journal, 62(4), Article 2300174. https://doi.org/10.1183/13993003.00174-2023

Vancouver

Frost F, Nazareth D, Fauchier L, Wat D, Shelley J, Austin P et al. Prevalence, risk factors and outcomes of cardiac disease in cystic fibrosis: A multinational retrospective cohort study. European Respiratory Journal. 2023 Oct 1;62(4):2300174. Epub 2023 Jul 20. doi: 10.1183/13993003.00174-2023

Author

Frost, Freddy ; Nazareth, Dilip ; Fauchier, Laurent et al. / Prevalence, risk factors and outcomes of cardiac disease in cystic fibrosis : A multinational retrospective cohort study. In: European Respiratory Journal. 2023 ; Vol. 62, No. 4.

Bibtex

@article{eb8a80eb24b048ef961c7f31239ca9f3,
title = "Prevalence, risk factors and outcomes of cardiac disease in cystic fibrosis: A multinational retrospective cohort study",
abstract = "INTRODUCTION: Although people living with cystic fibrosis (PwCF) often have some risk factors for cardiovascular disease including diabetes and chronic inflammation, little is known about the long-term cardiac risk in this condition. We aimed to determine the characteristics, rates, and outcomes for cardiac disease in cystic fibrosis.METHODS: We looked at rates and outcomes for cardiac disease in 5649 adult PwCF in the UK CF Registry and 6265 in TriNetX (a global federated database of electronic healthcare record data). We used propensity-matching to compare risk of major adverse cardiac events (myocardial infarction, left-sided heart failure, atrial fibrillation; MACE) in PwCF against matched non-CF comparators in the general population and other inflammatory diseases.RESULTS: PwCF had high prevalence of diabetes but low rates of hypertension and obesity. Some cardiac risk factors (age, diabetes, hypertension) were associated with MACE, but relationships between disease specific risk factors (lung function and intravenous antibiotic days) were also observed.In propensity-matched analyses, PwCF had higher risk of MACE than matched general population comparators (Hazard Ratio [95% CI] 1.65 [1.40 to 1.95], p<0.001), and an equivalent or higher relative risk compared to other inflammatory conditions considered {"}high-risk{"} for cardiovascular disease including rheumatoid arthritis (HR 1.21 [1.00 to 1.48], p<0.001), systemic lupus erythematosus (RR 0.95 [0.82 to 1.09], p=0.44) and human immunodeficiency virus (HR 0.93 [0.82 to 1.06], p=0.29) CONCLUSION: PwCF are at increased risk of adverse cardiac disease events. Future work should focus on defining determinants of cardiovascular risk such that appropriate risk stratification can be employed. ",
keywords = "Adult, Cystic Fibrosis/complications, Diabetes Mellitus/epidemiology, Heart Diseases, Humans, Hypertension, Myocardial Infarction/epidemiology, Prevalence, Retrospective Studies, Risk Factors",
author = "Freddy Frost and Dilip Nazareth and Laurent Fauchier and Dennis Wat and James Shelley and Philip Austin and Walshaw, {Martin J} and Lip, {Gregory Y H}",
year = "2023",
month = oct,
day = "1",
doi = "10.1183/13993003.00174-2023",
language = "English",
volume = "62",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "4",

}

RIS

TY - JOUR

T1 - Prevalence, risk factors and outcomes of cardiac disease in cystic fibrosis

T2 - A multinational retrospective cohort study

AU - Frost, Freddy

AU - Nazareth, Dilip

AU - Fauchier, Laurent

AU - Wat, Dennis

AU - Shelley, James

AU - Austin, Philip

AU - Walshaw, Martin J

AU - Lip, Gregory Y H

PY - 2023/10/1

Y1 - 2023/10/1

N2 - INTRODUCTION: Although people living with cystic fibrosis (PwCF) often have some risk factors for cardiovascular disease including diabetes and chronic inflammation, little is known about the long-term cardiac risk in this condition. We aimed to determine the characteristics, rates, and outcomes for cardiac disease in cystic fibrosis.METHODS: We looked at rates and outcomes for cardiac disease in 5649 adult PwCF in the UK CF Registry and 6265 in TriNetX (a global federated database of electronic healthcare record data). We used propensity-matching to compare risk of major adverse cardiac events (myocardial infarction, left-sided heart failure, atrial fibrillation; MACE) in PwCF against matched non-CF comparators in the general population and other inflammatory diseases.RESULTS: PwCF had high prevalence of diabetes but low rates of hypertension and obesity. Some cardiac risk factors (age, diabetes, hypertension) were associated with MACE, but relationships between disease specific risk factors (lung function and intravenous antibiotic days) were also observed.In propensity-matched analyses, PwCF had higher risk of MACE than matched general population comparators (Hazard Ratio [95% CI] 1.65 [1.40 to 1.95], p<0.001), and an equivalent or higher relative risk compared to other inflammatory conditions considered "high-risk" for cardiovascular disease including rheumatoid arthritis (HR 1.21 [1.00 to 1.48], p<0.001), systemic lupus erythematosus (RR 0.95 [0.82 to 1.09], p=0.44) and human immunodeficiency virus (HR 0.93 [0.82 to 1.06], p=0.29) CONCLUSION: PwCF are at increased risk of adverse cardiac disease events. Future work should focus on defining determinants of cardiovascular risk such that appropriate risk stratification can be employed.

AB - INTRODUCTION: Although people living with cystic fibrosis (PwCF) often have some risk factors for cardiovascular disease including diabetes and chronic inflammation, little is known about the long-term cardiac risk in this condition. We aimed to determine the characteristics, rates, and outcomes for cardiac disease in cystic fibrosis.METHODS: We looked at rates and outcomes for cardiac disease in 5649 adult PwCF in the UK CF Registry and 6265 in TriNetX (a global federated database of electronic healthcare record data). We used propensity-matching to compare risk of major adverse cardiac events (myocardial infarction, left-sided heart failure, atrial fibrillation; MACE) in PwCF against matched non-CF comparators in the general population and other inflammatory diseases.RESULTS: PwCF had high prevalence of diabetes but low rates of hypertension and obesity. Some cardiac risk factors (age, diabetes, hypertension) were associated with MACE, but relationships between disease specific risk factors (lung function and intravenous antibiotic days) were also observed.In propensity-matched analyses, PwCF had higher risk of MACE than matched general population comparators (Hazard Ratio [95% CI] 1.65 [1.40 to 1.95], p<0.001), and an equivalent or higher relative risk compared to other inflammatory conditions considered "high-risk" for cardiovascular disease including rheumatoid arthritis (HR 1.21 [1.00 to 1.48], p<0.001), systemic lupus erythematosus (RR 0.95 [0.82 to 1.09], p=0.44) and human immunodeficiency virus (HR 0.93 [0.82 to 1.06], p=0.29) CONCLUSION: PwCF are at increased risk of adverse cardiac disease events. Future work should focus on defining determinants of cardiovascular risk such that appropriate risk stratification can be employed.

KW - Adult

KW - Cystic Fibrosis/complications

KW - Diabetes Mellitus/epidemiology

KW - Heart Diseases

KW - Humans

KW - Hypertension

KW - Myocardial Infarction/epidemiology

KW - Prevalence

KW - Retrospective Studies

KW - Risk Factors

U2 - 10.1183/13993003.00174-2023

DO - 10.1183/13993003.00174-2023

M3 - Journal article

C2 - 37474158

VL - 62

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - 4

M1 - 2300174

ER -